Investigational Drug Information for Alisertib
✉ Email this page to a colleague
What is the development status for investigational drug Alisertib?
Alisertib is an investigational drug.
There have been 59 clinical trials for Alisertib.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2018.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
Summary for Alisertib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 403 |
| WIPO Patent Applications | 365 |
| Japanese Patent Applications | 51 |
| Clinical Trial Progress | Phase 3 (2018-09-01) |
| Vendors | 58 |
Recent Clinical Trials for Alisertib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Puma Biotechnology, Inc. | Phase 2 |
| Phase II Study of Chiauranib Capsule in Advanced or Unresectable Soft Tissue Sarcoma | Shenzhen Chipscreen Biosciences Co.Ltd | Phase 2 |
| Phase II Study of Chiauranib Capsule in Advanced or Unresectable Soft Tissue Sarcoma | Sun Yat-sen University | Phase 2 |
Clinical Trial Summary for Alisertib
Top disease conditions for Alisertib
Top clinical trial sponsors for Alisertib
US Patents for Alisertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
